A carregar...
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
PURPOSE: The SP142 PD-L1 assay is a companion diagnostic for atezolizumab in metastatic triple-negative breast cancer (TNBC). We strove to understand the biological, genomic, and clinical characteristics associated with SP142 PD-L1 positivity in TNBC patients. METHODS: Using 149 TNBC formalin-fixed...
Na minha lista:
| Publicado no: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8233296/ https://ncbi.nlm.nih.gov/pubmed/33770313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06193-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|